Compare Strategy Inc. (MSTR) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Strategy Inc. vs Smith & Nephew plc — how do they compare? Strategy Inc. trades at $154.98 (market cap $61.16B), while Smith & Nephew plc trades at $26.9 (market cap $11.31B). The key difference: Strategy Inc. is far larger — about 5.4× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.95% dividend while Strategy Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Strategy Inc. for 112 Days and Smith & Nephew plc for 120 Days on average.
| MSTR | SNN | |
|---|---|---|
Market Cap | $61.16B | $11.31B |
Volume | 21,318,561 | 1,050,005 |
Sector | Technology | Health |
52-Week High | $320.29 | $37.17 |
52-Week Low | $82.31 | $26.42 |
Typical Hold Time | 112 Days | 120 Days |
Enterprise Value | $79.92B | $14.35B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTR stock trades at $151.47, down 7.95% over 24 hours, with a bullish technical signal from moving averages. The company reported a net loss of $3.85 billion for 2025 on revenue of $477.23 million, with a deeply negative net income margin of -6,102.96%. Despite severe profitability challenges, analyst consensus remains optimistic with a $252 price target, and recent news highlights significant stock volatility tied to Bitcoin market movements.
The outlook is bifurcated: strong analyst buy ratings and a high price target suggest upside potential, but fundamental weaknesses including persistent losses and negative cash flow from operations pose substantial risks. Investment appeal hinges on speculative sentiment rather than current financial health, with volatility expected to continue.
SNN trades at $26.96, near its 52-week low, with a bearish technical signal. The company has shown improving fundamentals, with revenue growing from $5.2B in 2022 to $6.16B in 2025 and net income margin expanding to 10.08%. Recent product launches, like the EVOS PELVIC System, highlight innovation, but the stock faces negative sentiment from analyst downgrades and CFO departure news.
The outlook is mixed: strong profitability and cash flow support value, but bearish technicals and cautious analyst consensus (26% buy, 65% hold) suggest limited near-term upside. Key risks include execution challenges and competitive pressures. Investors should weigh solid fundamentals against weak market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
